Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 8/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.49 |
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | JAK1 | P23458 | 2/20 | 0.38 |
| ▸ | TYK2 | P29597 | 2/20 | 0.38 |
| ▸ | JAK3 | P52333 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2883291 | 1.00 | MCHR1 (0.49) | MCHR1KCNH2JAK2JAK1TYK2 | |
| SCHEMBL2878480 | 0.89 | MCHR1 (0.46) | MCHR1KCNH2JAK2JAK1TYK2 | |
| SCHEMBL2878478 | 0.89 | MCHR1 (0.46) | MCHR1KCNH2JAK2JAK1TYK2 | |
| SCHEMBL2894052 | 0.86 | MCHR1 (0.42) | MCHR1KCNH2JAK2JAK1TYK2 | |
| SCHEMBL2894055 | 0.86 | MCHR1 (0.42) | MCHR1KCNH2JAK2JAK1TYK2 | |
| SCHEMBL2877692 | 0.83 | MCHR1 (0.45) | MCHR1KCNH2JAK2JAK1TYK2 | |
| SCHEMBL2877695 | 0.83 | MCHR1 (0.45) | MCHR1KCNH2JAK2JAK1TYK2 | |
| SCHEMBL2884088 | 0.82 | MCHR1 (0.43) | MCHR1KCNH2DRD2ADRA1ASIGMAR1 | |
| SCHEMBL2884090 | 0.82 | MCHR1 (0.43) | MCHR1KCNH2DRD2ADRA1ASIGMAR1 | |
| SCHEMBL2882795 | 0.81 | MCHR1 (0.44) | MCHR1KCNH2DRD2ADRA1AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324049-A1 | DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR | MSD K.K. (JP) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324049-A1 | DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR | MC1R, MCHR1, MCHR2 | MCHR1 2/4885KCNH2 565/4885JAK2 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.